Filing Analysis
BioCardia, Inc. issued a press release on June 18, 2026, containing a letter to shareholders. The letter provides general updates regarding the company's business strategy, top priorities, and business development opportunities.
📋 Key Facts
- The filing date is June 18, 2026.
- The company released a shareholder letter via a press release (Exhibit 99.1).
- The content focuses on business strategy and development opportunities.
BioCardia reports that it believes it has regained compliance with Nasdaq Listing Rule 5550(b)(1) regarding the minimum $2.5 million stockholders' equity requirement. This was achieved through an 'At The Market' offering that raised $4.9 million in net proceeds between April 1 and June 5, 2026.
🚩 Red Flags
- Recent failure to meet minimum equity requirements for exchange listing.
- Heavy reliance on equity dilution (ATM offering) to solve regulatory compliance issues.
- Nasdaq will continue to monitor compliance, and failure in the next periodic report could lead to delisting.
📋 Key Facts
- Company was notified on April 10, 2026, that stockholders' equity fell below the required $2.5 million minimum.
- Nasdaq granted an extension until October 7, 2026, to regain compliance.
- The company sold 4,004,330 shares via an ATM offering with H.C. Wainwright & Co. between April 1, 2026, and June 5, 2026.
- Net proceeds from the offering totaled $4.9 million at an average share price of $1.27.
- The company believes stockholders' equity now exceeds the $2.5 million threshold.
BioCardia, Inc. announced the sale of 3,509,604 shares of common stock via its 'At The Market' (ATM) offering agreement with H.C. Wainwright & Co. The transactions occurred on June 5, 2026, at an average price of $1.279 per share.
🚩 Red Flags
- Dilution: The issuance of over 3.5 million shares increases the total share count, potentially diluting existing shareholders.
📋 Key Facts
- Total shares sold: 3,509,604
- Average sale price: $1.279 per share
- Transaction date: June 5, 2026
- Offering mechanism: 'At The Market' (ATM) agreement
- Underwriter: H.C. Wainwright & Co.
BioCardia announced that it received meeting minutes from the FDA's Center for Biologics Evaluation and Research (CBER) regarding the CardiAMP Cell Therapy System. The minutes confirm that the ongoing CardiAMP Heart Failure II Trial can be used to support a Premarket Approval (PMA) application for treating ischemic heart failure.
📋 Key Facts
- FDA meeting minutes received on June 5, 2026.
- The focus is on the CardiAMP Cell Therapy System for ischemic heart failure of reduced ejection fraction (HFrEF).
- FDA confirmed the CardiAMP Heart Failure II Trial is sufficient to support a Premarket Approval (PMA) for market clearance.
BioCardia, Inc. announced that Japan's PMDA supports the submission for regulatory approval of CardiAMP® cell therapy for ischemic heart failure (HFrEF) based on three completed clinical trials.
📋 Key Facts
- PMDA supports submission for regulatory approval for ischemic HFrEF patients with elevated biomarkers of heart stress (NTproBNP) on stable guideline directed medical therapy (GDMT).
- PMDA noted that positive outcomes seen in the trial were credible.
- Estimated initial eligible patient population in Japan is 20,000 out of 300,000 patients.
- PMDA requested additional documentation regarding patient GDMT status, revascularization eligibility, and details on all-cause death, transplantation, or LVAD implantation.
- Clinical results showed increased exercise tolerance (average improvement of 179 seconds) and an 82% reduction in angina episodes by six months.
BioCardia announced positive two-year follow-up results from the preliminary open-label cohort of its CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial (CardiAMP CMI) at the Euro PCR conference. The data demonstrated that the therapy was well tolerated and resulted in sustained improvements in exercise tolerance and a significant reduction in angina episodes.
📋 Key Facts
- Presented results of the CardiAMP CMI preliminary open-label cohort at the Euro PCR conference in Paris on May 21, 2026.
- The minimally invasive procedure was well tolerated with no treatment-emergent major adverse cardiac events reported.
- Patients demonstrated an average increase in exercise tolerance of 179 seconds, which persisted through the two-year follow-up period.
- Angina episodes were reduced by an average of 82% at six months post-treatment.
BioCardia, Inc. announced its financial results for the first quarter ended March 31, 2026, via a press release. The filing serves as a routine quarterly earnings update furnished to the SEC.
📋 Key Facts
- Financial results for the quarter ended March 31, 2026, were released on May 15, 2026.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition).
- A press release was included as Exhibit 99.1.
BioCardia announced positive feedback from an FDA Pre-Submission Meeting regarding its Helix Transendocardial Delivery Catheter System. The FDA confirmed two potential marketing clearance pathways and raised no concerns regarding the device's safety or performance.
🚩 Red Flags
- The preferred regulatory pathway ties the Helix system's approval to the success and timing of the CardiAMP cell therapy system.
📋 Key Facts
- FDA identified two distinct pathways for Helix marketing clearance.
- FDA raised no concerns regarding Helix safety data, device performance, or compatibility with general classes of agents.
- FDA's preferred route for Helix approval is simultaneous with the approval of the CardiAMP cell therapy system for heart failure.
- FDA suggested a follow-on pre-submission could enable Helix approval via the DeNovo pathway.
- The meeting outcome was disclosed via a press release on May 8, 2026.
BioCardia announced the allowance of a Japanese patent for its Heart3D™ Fusion Imaging software. The patent covers technology used for treatment planning and real-time navigation during the company's CardiAMP Cell Therapy procedures.
📋 Key Facts
- Allowance of Japanese Patent titled 'Target Site Selection, Entry, and Update with Automatic Remote Image Annotation' on April 28, 2026
- The patent protects Heart3D™ Fusion Imaging (Heart3D) software
- The technology is intended for treatment planning and real-time navigation during CardiAMP Cell Therapy procedures
- The disclosure was made under Item 8.01 (Other Events) and included a press release as Exhibit 99.1
BioCardia announced a positive outcome from its formal clinical consultation with Japan's PMDA, which indicated that existing US clinical data for the CardiAMP Cell Therapy is likely sufficient for market clearance in Japan. The company achieved alignment on the use of foreign data, indications for use, and post-marketing study requirements.
📋 Key Facts
- Formal consultation with Japan's Pharmaceutical and Medical Device Agency (PMDA) occurred on April 20, 2026.
- PMDA determined that US clinical safety and efficacy evidence for CardiAMP is likely sufficient for Japanese market clearance.
- Alignment was reached on the acceptability of foreign clinical data and the approach for therapy introduction in Japan.
- The company is awaiting official minutes from the PMDA to provide a detailed feedback and filing timeline.
BioCardia, Inc. received a deficiency notice from Nasdaq on April 10, 2026, for failing to maintain the minimum stockholders' equity requirement of $2.5 million. The company's reported equity was $895,000 as of December 31, 2025, significantly below the threshold.
🚩 Red Flags
- Stockholders' equity is approximately 64% below the required minimum threshold.
- The deficiency indicates substantial capital depletion as of the end of fiscal year 2025.
- Risk of delisting if the compliance plan is rejected or if the company fails to raise sufficient capital.
📋 Key Facts
- Received Nasdaq notice on April 10, 2026, regarding non-compliance with Listing Rule 5550(b)(1).
- Stockholders' equity was $895,000 as of December 31, 2025, versus the $2.5 million requirement.
- The company has until May 25, 2026, to submit a plan to regain compliance.
- If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from the notice date.
- The notice does not result in immediate delisting; the stock continues to trade under 'BCDA'.
BioCardia announced the submission of CardiAMP HF clinical study data to the FDA and plans to discuss an accelerated approval pathway for its heart failure treatment system.
📋 Key Facts
- Submitted CardiAMP HF clinical study data to the FDA on April 2, 2026.
- Seeking accelerated approval pathway for the CardiAMP System for ischemic chronic heart failure with reduced ejection fraction (HFrEF).
- Plans to meet with the FDA to discuss the regulatory pathway for the device.
- The information was disclosed under Item 7.01 (Regulation FD) via a press release.
BioCardia, Inc. announced its financial results for the fiscal year ended December 31, 2025, via a press release on March 24, 2026.
📋 Key Facts
- The company reported financial results for the full year ended December 31, 2025.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the results was furnished as Exhibit 99.1.
- The filing was signed by CEO Peter Altman, Ph.D.
BioCardia, Inc. announced that the FDA has accepted its pre-submission package for the Helix Transendocardial Delivery Catheter. The device is intended for the delivery of therapeutic and diagnostic agents directly into the heart muscle.
📋 Key Facts
- The FDA accepted the pre-submission package on March 17, 2026.
- The product involved is the Helix Transendocardial Delivery Catheter ('Helix').
- The device is designed for intramyocardial therapeutic and diagnostic agent delivery.
- The filing was made under Item 8.01 (Other Events).
BioCardia announced late-breaking echocardiography results from its Phase III CardiAMP HF clinical trial for ischemic heart failure. The data was presented at the Technology and Heart Failure Therapeutics conference on March 3, 2026.
📋 Key Facts
- The company reported Phase III clinical trial results for ischemic heart failure of reduced ejection fraction (HFrEF).
- Results were presented by Dr. Amish Raval, National Co-Principal Investigator, at the Technology and Heart Failure Therapeutics conference.
- The disclosure was made under Item 7.01 (Regulation FD) and included a press release as Exhibit 99.1.
- The presentation occurred on March 3, 2026.